{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02192736",
      "OrgStudyIdInfo": {
        "OrgStudyId": "TBS-MTFAS-001"
      },
      "Organization": {
        "OrgFullName": "Translational Biosciences",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma",
      "OfficialTitle": "Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 2020",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2020",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 14, 2014",
      "StudyFirstSubmitQCDate": "July 15, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 17, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 25, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 26, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Translational Biosciences",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Allogeneic mesenchymal trophic factors (MTF) from human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) administered intra-nasally to 20 patients is a safe and useful procedure for inducing improvements in pulmonary function and quality of life in patients with asthma.",
      "DetailedDescription": "The proposed study will assess primary safety and secondary efficacy endpoints of allogeneic UC-MSC-derived MTF administered to patients with asthma. Each patient will receive intra-nasal MTF once per week for a period of 4 weeks."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Asthma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "asthma",
          "umbilical cord",
          "mesenchymal",
          "stem cells",
          "trophic factors"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Intra-nasal infusion of MTF",
            "ArmGroupType": "Other",
            "ArmGroupDescription": "Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Trophic factors from umbilical cord mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Intra-nasal infusion of MTF"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of patients with adverse events",
            "PrimaryOutcomeDescription": "Evaluated 1 month after the final treatment",
            "PrimaryOutcomeTimeFrame": "1 month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of patients with a change in pulmonary function from baseline as measured by Forced Expiratory Volume (FEV1) following American Thoracic Society (ATS) guidelines",
            "SecondaryOutcomeDescription": "After first treatment\nAfter final treatment",
            "SecondaryOutcomeTimeFrame": "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 month"
          },
          {
            "SecondaryOutcomeMeasure": "Number of patients with a change in pulmonary function from baseline as measured by Forced Vital Capacity (FVC) following American Thoracic Society (ATS) guidelines",
            "SecondaryOutcomeDescription": "After first treatment\nAfter final treatment",
            "SecondaryOutcomeTimeFrame": "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 monrh"
          },
          {
            "SecondaryOutcomeMeasure": "Number of patients with a change in quality of life from baseline as measured by the University of Pittsburgh Medical Center (UPMC) Asthma Questionnaire",
            "SecondaryOutcomeDescription": "After first treatment\nAfter last treatment",
            "SecondaryOutcomeTimeFrame": "a) 1 week, 2 weeks, 3 weeks, 4 weeks b) 1 month"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSigned consent form by the subject\nMale or female\nBetween 18 and 65 years old and capability to comprehend this trial.\nAsthma diagnosed by a physician at least 1 year prior to study enrollment\nPoorly-controlled asthma at study enrollment. Poorly controlled asthma is defined as: chronic symptoms, episodic exacerbations, persistent and variable airways obstruction despite a continued requirement for short-acting beta 2-agonists despite the use of high doses of inhaled steroids.\nNonsmokers (stopped smoking at least 1 year ago) and limited life-time history of smoking (less than a 3 pack year history).\nBody mass index 19-40\nOn a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry or had to use a rescue dose during the last 4 weeks.\nFEV1 >50% predicted\n\nExclusion Criteria:\n\nPregnant or lactating women\nCognitively impaired adults\nSystemic steroids within the 4 weeks prior to enrollment\nNon-steroidal anti-inflammatory drugs (NSAIDs) for arthritis\nCurrent diagnosis of polyposis or sinusitis.\nInfection treated by antibiotics within the 4 weeks prior to enrollment\nImmunization within the 4 weeks prior to enrollment\nLung pathology other than asthma\nOther significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction <50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine >3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis\nIllicit drug use within the past year\nCurrent/active upper respiratory infection (URI) (if active URI, wait until asymptomatic for 1 week to enroll)\nAsthma exacerbation within the 4 weeks prior to enrollment (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)\nUndergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months prior to enrollment will be allowed to participate)\nClinically significant abnormalities present on screening 12-lead electrocardiogram\nWomen of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study\nParticipation in another clinical study within 4 weeks prior to enrollment\nSubject does not sign informed consent",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "21 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Moises Zebede, MD",
            "OverallOfficialAffiliation": "Punta Pacifia Hospital in Panama City, Panama",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Punta Pacifica Hospital",
            "LocationCity": "Panama City",
            "LocationCountry": "Panama"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001249",
            "ConditionMeshTerm": "Asthma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001982",
            "ConditionAncestorTerm": "Bronchial Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000008173",
            "ConditionAncestorTerm": "Lung Diseases, Obstructive"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012130",
            "ConditionAncestorTerm": "Respiratory Hypersensitivity"
          },
          {
            "ConditionAncestorId": "D000006969",
            "ConditionAncestorTerm": "Hypersensitivity, Immediate"
          },
          {
            "ConditionAncestorId": "D000006967",
            "ConditionAncestorTerm": "Hypersensitivity"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3708",
            "ConditionBrowseLeafName": "Asthma",
            "ConditionBrowseLeafAsFound": "Asthma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4410",
            "ConditionBrowseLeafName": "Bronchial Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10322",
            "ConditionBrowseLeafName": "Lung Diseases, Obstructive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9170",
            "ConditionBrowseLeafName": "Hypersensitivity",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14119",
            "ConditionBrowseLeafName": "Respiratory Hypersensitivity",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9172",
            "ConditionBrowseLeafName": "Hypersensitivity, Immediate",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}